Vaccine and Emerging Infections Research, Human Health Therapeutics Research Centre, National Research Council, Ottawa, ON, K1A 0R6, Canada
Fusobacterium nucleatum is a gram-negative bacterium, part of the normal human microflora. It is associated with various health complications, including periodontitis and colorectal cancer. Its surface is covered with lipopolysaccharide, which interacts with the immune system and can be involved in various processes in health and disease conditions. Here we present the results of structural analysis of core oligosaccharides from the lipopolysaccharides of several strains of F. nucleatum. Pure compounds were isolated using mild acid hydrolysis or alkaline deacylation of the lipopolysaccharides and analyzed by NMR spectroscopy, mass-spectrometry and chemical methods. All cores analyzed had a common octasaccharide region, including five heptose residues and a non-phosphorylated 3-deoxy-d-manno-oct-2-ulosonic acid residue. The common region is substituted with different additional components specific for each strain. By structure type the F. nucleatum core is similar to that produced by Aeromonas.
table 1, Fig.1, table S4, Hex1Hep5HexN4dHexNN1HexNNAN1Ac2Am1Fo1Pro1anhKdo1P3Cho1
13C NMR, 1H NMR, NMR-2D, 31P NMR, ESI-MS, mild acid hydrolysis, HPAEC, chemical methods, deamination, GPC, alkaline deacylation, fermentation
13C NMR data:
Linkage Residue C1 C2 C3 C4 C5 C6 C7 C8 C9
5,3,2,7 aDGlcpN 96.8 55.4 71.7 70.7 73.9 61.7
5,3,2 aXLLmanHepp 103.0 72.1 72.1 67.5 73.5 69.2 71.7
5,3 aXLLmanHepp 99.7 81.4 71.3 67.6 73.0 70.4 65.0
5,4,4,4,6,3,4,5 Am 167.2 19.8
5,4,4,4,6,3,4,7 Ac 175.2 23.6
5,4,4,4,6,3,4 bXDL3,9dglcNonp5N7N-ulosonic 175.6 99.6 36.0 66.0 51.8 69.5 53.7 65.9 17.9
5,4,4,4,6,3,3 Fo 171.5
5,4,4,4,6,3,6 NH2
5,4,4,4,6,3 bDGlcpN3NA 103.5 54.4 53.2 72.5 79.3 176.5
5,4,4,4,6,2 Ac 175.2 23.6
5,4,4,4,6 bDFucpN4N 103.1 51.9 77.7 55.6 68.6 16.7
5,4,4,4 aDGlcpN 97.2 55.4 70.9 70.6 72.2 69.2
5,4,4,6 P
5,4,4 bDGalp 104.2 71.5 72.9 77.7 73.5 63.5
5,4,6,6,6,0 xXCho 60.8 67.3 55.2
5,4,6,6,6 %xXP?
5,4,6,6 aDGlcpN 96.3 55.5 70.7 70.2 72.8 65.5
5,4,6 aXLLmanHepp 102.3 70.7 72.3 67.6 74.0 76.9 63.7
5,4 bDGlcpN 100.7 57.9 73.0 77.2 75.6 66.6
5,6 aXLLmanHepp 102.3 71.9 71.5 67.6 73.9 70.7 64.3
5,7 P
5 aXLLmanHepp 103.5 71.3 73.7 75.6 71.1 76.7 64.2
??Sug?
5,4,4,4,6,3,2 30%lXBut 179.0 39.1 20.3 13.6
5,4,4,4,6,3,2 70%Pp 179.0 30.4 10.7
1H NMR data:
Linkage Residue H1 H2 H3 H4 H5 H6 H7 H8 H9
5,3,2,7 aDGlcpN 5.10 3.47 3.89 3.66 3.74 3.87-3.92
5,3,2 aXLLmanHepp 5.20 4.01 4.01 3.84 3.85 4.34 3.54-4.01
5,3 aXLLmanHepp 5.69 3.97 3.91 3.91 3.63 4.08 3.69-3.83
5,4,4,4,6,3,4,5 Am ? 2.38
5,4,4,4,6,3,4,7 Ac - 2.05
5,4,4,4,6,3,4 bXDL3,9dglcNonp5N7N-ulosonic - - 1.86-2.56 4.12 3.52 4.14 3.93 4.54 1.12
5,4,4,4,6,3,3 Fo 8.07
5,4,4,4,6,3,6 NH2
5,4,4,4,6,3 bDGlcpN3NA 4.74 3.88 4.11 4.21 3.81 -
5,4,4,4,6,2 Ac - 2.05
5,4,4,4,6 bDFucpN4N 4.51 3.85 4.13 3.94 4.01 1.35
5,4,4,4 aDGlcpN 5.33 3.28 3.88 3.49 4.41 3.81-4.08
5,4,4,6 P
5,4,4 bDGalp 4.53 3.63 3.91 4.20 3.83 3.90-3.98
5,4,6,6,6,0 xXCho 4.34 3.68 3.23
5,4,6,6,6 %xXP?
5,4,6,6 aDGlcpN 5.59 3.43 4.00 3.63 4.01 4.17-4.17
5,4,6 aXLLmanHepp 5.06 3.97 3.73 3.94 3.90 4.28 3.93-3.97
5,4 bDGlcpN 4.78 3.29 3.67 3.83 3.69 3.99-4.10
5,6 aXLLmanHepp 5.29 4.01 3.91 3.85 3.77 4.04 3.73-3.86
5,7 P
5 aXLLmanHepp 5.15 4.18 3.96 4.34 4.08 4.11 4.05-4.16
??Sug?
5,4,4,4,6,3,2 30%lXBut - 2.05 1.43 0.74
5,4,4,4,6,3,2 70%Pp - 2.05-2.10 0.93
1H/13C HSQC data:
Linkage Residue C1/H1 C2/H2 C3/H3 C4/H4 C5/H5 C6/H6 C7/H7 C8/H8 C9/H9
5,3,2,7 aDGlcpN 96.8/5.10 55.4/3.47 71.7/3.89 70.7/3.66 73.9/3.74 61.7/3.87-3.92
5,3,2 aXLLmanHepp 103.0/5.20 72.1/4.01 72.1/4.01 67.5/3.84 73.5/3.85 69.2/4.34 71.7/3.54-4.01
5,3 aXLLmanHepp 99.7/5.69 81.4/3.97 71.3/3.91 67.6/3.91 73.0/3.63 70.4/4.08 65.0/3.69-3.83
5,4,4,4,6,3,4,5 Am 167.2/? 19.8/2.38
5,4,4,4,6,3,4,7 Ac 23.6/2.05
5,4,4,4,6,3,4 bXDL3,9dglcNonp5N7N-ulosonic 36.0/1.86-2.56 66.0/4.12 51.8/3.52 69.5/4.14 53.7/3.93 65.9/4.54 17.9/1.12
5,4,4,4,6,3,3 Fo 171.5/8.07
5,4,4,4,6,3,6 NH2
5,4,4,4,6,3 bDGlcpN3NA 103.5/4.74 54.4/3.88 53.2/4.11 72.5/4.21 79.3/3.81
5,4,4,4,6,2 Ac 23.6/2.05
5,4,4,4,6 bDFucpN4N 103.1/4.51 51.9/3.85 77.7/4.13 55.6/3.94 68.6/4.01 16.7/1.35
5,4,4,4 aDGlcpN 97.2/5.33 55.4/3.28 70.9/3.88 70.6/3.49 72.2/4.41 69.2/3.81-4.08
5,4,4,6 P
5,4,4 bDGalp 104.2/4.53 71.5/3.63 72.9/3.91 77.7/4.20 73.5/3.83 63.5/3.90-3.98
5,4,6,6,6,0 xXCho 60.8/4.34 67.3/3.68 55.2/3.23
5,4,6,6,6 %xXP?
5,4,6,6 aDGlcpN 96.3/5.59 55.5/3.43 70.7/4.00 70.2/3.63 72.8/4.01 65.5/4.17-4.17
5,4,6 aXLLmanHepp 102.3/5.06 70.7/3.97 72.3/3.73 67.6/3.94 74.0/3.90 76.9/4.28 63.7/3.93-3.97
5,4 bDGlcpN 100.7/4.78 57.9/3.29 73.0/3.67 77.2/3.83 75.6/3.69 66.6/3.99-4.10
5,6 aXLLmanHepp 102.3/5.29 71.9/4.01 71.5/3.91 67.6/3.85 73.9/3.77 70.7/4.04 64.3/3.73-3.86
5,7 P
5 aXLLmanHepp 103.5/5.15 71.3/4.18 73.7/3.96 75.6/4.34 71.1/4.08 76.7/4.11 64.2/4.05-4.16
??Sug?
5,4,4,4,6,3,2 30%lXBut 39.1/2.05 20.3/1.43 13.6/0.74
5,4,4,4,6,3,2 70%Pp 30.4/2.05-2.10 10.7/0.93